Wall Street analysts predict that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) will post earnings of ($0.93) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Paratek Pharmaceuticals’ earnings. The highest EPS estimate is ($0.87) and the lowest is ($1.04). Paratek Pharmaceuticals reported earnings of ($1.04) per share in the same quarter last year, which would indicate a positive year over year growth rate of 10.6%. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 1st.
On average, analysts expect that Paratek Pharmaceuticals will report full-year earnings of ($3.53) per share for the current fiscal year, with EPS estimates ranging from ($3.95) to ($3.20). For the next financial year, analysts forecast that the company will post earnings of ($3.31) per share, with EPS estimates ranging from ($3.99) to ($2.59). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that cover Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to analysts’ expectations of $7.50 million.
A number of brokerages recently issued reports on PRTK. BidaskClub upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Paratek Pharmaceuticals in a research note on Tuesday, August 8th. Zacks Investment Research lowered Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Raymond James Financial, Inc. reiterated a “strong-buy” rating and set a $36.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, August 24th. Finally, HC Wainwright lifted their price objective on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, July 18th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $37.44.
Paratek Pharmaceuticals (NASDAQ:PRTK) opened at 24.75 on Friday. Paratek Pharmaceuticals has a 1-year low of $9.80 and a 1-year high of $29.00. The stock’s market cap is $687.08 million. The stock has a 50 day moving average price of $23.00 and a 200 day moving average price of $21.50.
ILLEGAL ACTIVITY WARNING: “Brokerages Expect Paratek Pharmaceuticals, Inc. (PRTK) Will Announce Earnings of -$0.93 Per Share” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/17/brokerages-expect-paratek-pharmaceuticals-inc-prtk-will-announce-earnings-of-0-93-per-share.html.
In other news, VP Adam Woodrow sold 3,800 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $89,604.00. Following the transaction, the vice president now directly owns 69,500 shares in the company, valued at approximately $1,638,810. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Douglas W. Pagan sold 4,139 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $97,597.62. Following the transaction, the chief financial officer now owns 60,000 shares in the company, valued at $1,414,800. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,960 shares of company stock worth $524,342. Insiders own 4.90% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Legal & General Group Plc boosted its holdings in shares of Paratek Pharmaceuticals by 13.3% during the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock worth $144,000 after purchasing an additional 687 shares during the last quarter. Quantbot Technologies LP acquired a new position in Paratek Pharmaceuticals in the second quarter valued at approximately $172,000. Citigroup Inc. lifted its holdings in Paratek Pharmaceuticals by 19,470.0% in the second quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after acquiring an additional 7,788 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Paratek Pharmaceuticals in the second quarter valued at approximately $200,000. Finally, Appleton Partners Inc. MA acquired a new position in Paratek Pharmaceuticals in the second quarter valued at approximately $220,000. Institutional investors and hedge funds own 82.33% of the company’s stock.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.